Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.

Alexandra Albertsson-LindbladCatja FreiburghausMats JerkemanSara Ek

Published in: Experimental hematology & oncology (2019)

Ibrutinib negatively affects anti-CD20 induced cell death in MCL, not reversed by lenalidomide. Explorations of sequential administration and selective BTK-inhibitors may reveal the optimal combination of novel agents in MCL.

Keyphrases

chronic lymphocytic leukemia
cell death
high glucose
diabetic rats
tyrosine kinase
genome wide
multiple myeloma
single cell
drug induced
gene expression
oxidative stress
low dose
endothelial cells
high dose